Table 2 Association between biomarkers at baseline, clinical covariates and overall survival for metastatic melanoma patients
Variable | HR | 95%Cl | p-value | |
|---|---|---|---|---|
PRO-C3 | Continuous | 1.03 | 1.02–1.05 | 0.0004 |
5.0–19.2 ng/ml, Q1-Q3 | 1.00 | – | – | |
Univariate | 19.6–113.3 ng/ml, Q4 | 2.13 | 1.12–4.04 | 0.021 |
5.0–19.2 ng/ml, Q1-Q3* | 1.00 | – | – | |
Multivariate | 19.6–113.3 ng/ml, Q4* | 2.04 | 1.00–4.16 | 0.049 |
C1M | Continuous | 1.01 | 1.00–1.01 | 0.005 |
20–46.6 ng/ml, Q1-Q3 | 1.00 | – | – | |
Univariate | 56.7–313.1 ng/ml, Q4 | 1.70 | 0.85–3.38 | 0.131 |
20–46.6 ng/ml, Q1-Q3* | 1.00 | – | – | |
Multivariate | 56.7–313.1 ng/ml, Q4* | 1.17 | 0.54–2.51 | 0.693 |
C3M | Continuous | 1.03 | 1.00–1.07 | 0.037 |
4.7–23.4, Q1-Q3 | 1.00 | – | – | |
Univariate | 23.6–68.8, Q4 | 1.60 | 0.82–3.13 | 0.167 |
4.7–23.4, Q1-Q3* | 1.00 | – | – | |
Multivariate | 23.6–68.8, Q4* | 1.06 | 0.48–2.33 | 0.886 |
C4M | Continuous | 1.04 | 1.01–1.08 | 0.026 |
11.9–34.7 ng/ml, Q1-Q3 | 1.00 | – | – | |
Univariate | 35.1–73.9 ng/ml, Q4 | 2.43 | 1.26–4.70 | 0.008 |
11.9–34.7 ng/ml, Q1-Q3* | 1.00 | – | – | |
Multivariate | 35.1–73.9 ng/ml, Q4* | 2.18 | 1.01–4.70 | 0.046 |
VICM | Continuous | 0.99 | 0.95–1.02 | 0.413 |
1.0–9.1 ng/ml, Q1-Q2 | 1.00 | – | – | |
Univariate | 9.1–41.3 ng/ml, Q3-Q4 | 0.54 | 0.29–0.99 | 0.044 |
1.0–9.1 ng/ml, Q1-Q2* | 1.00 | – | – | |
Multivariate | 9.1–41.3 ng/ml, Q3-Q4* | 0.49 | 0.26–0.92 | 0.026 |
Age at baseline | 1.02 | 0.99–1.04 | 0.254 | |
LDH at sampling | Continuous | 1.00 | 1.00–1.00 | 0.009 |
(> = 250 IU/L) | 2.02 | 0.99–4.12 | 0.052 | |
Prior systemic therapy | 1.32 | 0.73–2.40 | 0.363 | |